Iovance Biotherapeutics, Inc.
FormerlyLion Biotechnologies, Inc.
TypePublic company
Industry
Founded2007 (2007)
HeadquartersSan Carlos, California, U.S.
Key people
Steven Rosenberg
Number of employees
319 (December 31, 2021)
Websiteiovance.com

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.[3]

Drug pipeline

Iovance has a TIL treatment undergoing clinical trials against melanoma (investigational id: LN-144, tradename: Lifileucel).[4] Iovance is investigating a TIL therapy against cervical and head and neck cancers (investigational id: LN-145).

See also

References

  1. ↑ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
  2. ↑ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
  3. ↑ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
  4. ↑ Iovance Biotherapeutics, Inc. (2022-11-14). "An Expanded Access Program of Lifileucel, Autologous Tumor Infiltrating Lymphocytes (TIL; LN-144), for Patients With Unresectable or Metastatic Melanoma". {{cite journal}}: Cite journal requires |journal= (help)
  • Official website
  • Business data for Iovance Biotherapeutics, Inc.:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.